Earnings ·
Tiziana reports $12.4M H1 loss, raises $8.4M equity as cash drops to $3.9M
TLSATiziana Life Sciences Ltd
Tiziana Life Sciences reported a total comprehensive loss of $12.4 million for the six months ended June 30, 2026, compared to a $5.3 million loss in the prior year period. The company raised approximately $8.4 million net from the issuance of ordinary shares during the quarter. Cash and cash equivalents decreased to $3.2 million at June 30, with the balance falling further to $3.9 million by mid-October. Management disclosed a material uncertainty regarding its ability to continue as a going concern, citing significant cash outflows and the need to secure additional capital through equity raises or other measures to fund ongoing clinical trials for its lead asset, intranasal foralumab. The company is developing immunomodulation therapies for neurodegenerative and autoimmune diseases.